Announcements Trials
Browse Landscape

Status

No longer available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Meningeal Neoplasms 1Medulloblastoma 1Hepatoblastoma 1

Interventions

Suspensions 2Powders 2trametinib 1talquetamab 1taletrectinib 1sotorasib 1ruxolitinib 1revumenib 1patritumab deruxtecan 1omburtamab I-131 1leronlimab 1gallium maltolate 1dabrafenib 1ceritinib 1capmatinib 1asparaginase erwinia chrysanthemi recombinant 1apalutamide 1Standard of Care 1Paclitaxel 1Nivolumab 1HMPL-013 1Docetaxel 1Asparaginase 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × omburtamab I-131 × 1 year × Clear all
NCT05064306 2025-08-01

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Memorial Sloan Kettering Cancer Center

No longer available
CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Medulloblastoma, Meningeal Neoplasms, Wilms Tumor, Neuroblastoma, Pinealoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡